Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Traci McCartney

Nurse Practitioner Clarksville, IN Nurse Practitioner

NPI 1043275530 CMS profile 10965075

2051 Clevidence Blvd, Suite 1, Clarksville, IN 47129

Open in the dashboard

General payments

$3,117

73 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Traci McCartney of Clarksville, IN is reported in the CMS Open Payments database as having received $3,117 across 73 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $247 3
2024 General $476 5
2023 General $562 11
2022 General $542 23
2021 General $1,290 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Traci McCartney
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Traci McCartney were reported at $247. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Traci McCartney Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,290 $135 $40–$426 $132
2022 $542 $152 $48–$470 $149
2023 $562 $166 $54–$529 $160
2024 $476 $173 $55–$556 $164
2025 $247 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $914 12 payments
  2. AbbVie, Inc. $535 18 payments
  3. Novo Nordisk Inc $375 4 payments
  4. Sunovion Pharmaceuticals Inc. $213 17 payments
  5. Sumitomo Pharma America, Inc. $188 6 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $144 2 payments
  7. OptiNose US, Inc. $125 1 payment
  8. Myovant Sciences Inc. $125 1 payment
  9. Phathom Pharmaceuticals, Inc. $125 1 payment
  10. Biohaven Pharmaceuticals, Inc. $117 3 payments
  11. Other $258 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,085 71 payments
  2. Education $32 2 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $410 6 payments
  2. Ozempic $375 4 payments
  3. VRAYLAR $276 12 payments
  4. BREZTRI $271 5 payments
  5. GEMTESA $264 21 payments
  6. UBRELVY $259 6 payments
  7. AIRSUPRA $251 2 payments
  8. MYFEMBREE $248 2 payments
  9. Kerendia $144 2 payments
  10. Xhance $125 1 payment
  11. Other $563 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 133 drugs

Part D claims

6,285

Median for Nurse Practitioner: 389

Drug cost

$562,029

Median for Nurse Practitioner: $21,885

Branded share of claims

26.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 68 $79,905
Eliquis Apixaban Brand 84 $75,622
Jardiance Empagliflozin Brand 51 $43,850
Farxiga Dapagliflozin Propanediol Brand 24 $31,675
Rybelsus Semaglutide Brand 32 $31,138
Ozempic Semaglutide Brand 31 $29,834
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 26 $23,602
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 28 $21,806
Synjardy Xr Empagliflozin/Metformin Hcl Brand 13 $19,830
Tresiba Flextouch U-200 Insulin Degludec Brand 34 $18,657

The 10 drugs with the highest cost, of 133 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$62,482

Of which drugs: $19,148

Medicare patients

130

Average age 70

Services billed

6,515

82 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 35%
Depression 28%
Ischemic heart disease 22%
COPD 18%
Atrial fibrillation 15%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 39 48 $6,872
Vaccine for influenza for injection into muscle 90662 Office 47 48 $3,754

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $251
$251 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $125
$125 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $63
$63 24 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

73 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record